Can-Fite BioPharma (CANF) Current Assets (2014 - 2025)
Can-Fite BioPharma's (CANF) quarterly Current Assets came in at $9.4 million in Q4 2025, up 5.1% YoY from $9.0 million in Q4 2024, and up 23.82% on a QoQ basis from $7.6 million in Q2 2025.
Can-Fite BioPharma (CANF) Current Assets (2014 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 12 years of Current Assets data on file, last reported at $9.4 million in Q4 2025.
- Quarterly Current Assets rose 5.1% year-over-year to $9.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.4 million (up 5.1% YoY) and the FY2025 annual result came in at $9.4 million, up 5.1% from the prior year.
- Current Assets advanced to $9.4 million in Q4 2025, from $7.6 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $20.1 million in Q4 2021 to a low of $5.8 million in Q2 2024.
- A 5-year average of $11.6 million and a median of $10.4 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2021 — Current Assets soared 113.49% — and 2022, when it slumped 54.37%.
- Tracing CANF's Current Assets over 5 years: stood at $20.1 million in 2021, then tumbled by 54.37% to $9.2 million in 2022, then climbed by 8.2% to $9.9 million in 2023, then decreased by 9.35% to $9.0 million in 2024, then increased by 5.1% to $9.4 million in 2025.
- The last three Current Assets figures came in at $9.4 million (Q4 2025), $7.6 million (Q2 2025), and $9.0 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.76 Bn |
| 10 | Can-Fite BioPharma | 2.77 Mn | -8.78 Mn | - | 9.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.44 Mn |
| Jun 30, 2025 | 7.62 Mn |
| Dec 31, 2024 | 8.98 Mn |
| Jun 30, 2024 | 5.83 Mn |
| Dec 31, 2023 | 9.91 Mn |
| Sep 30, 2023 | 9.06 Mn |
| Jun 30, 2023 | 10.91 Mn |
| Mar 31, 2023 | 13.38 Mn |
| Dec 31, 2022 | 9.16 Mn |
| Sep 30, 2022 | 12.57 Mn |
| Jun 30, 2022 | 14.59 Mn |
| Mar 31, 2022 | 17.67 Mn |
| Dec 31, 2021 | 20.07 Mn |
| Sep 30, 2021 | 14.47 Mn |
| Jun 30, 2021 | 9.55 Mn |
| Mar 31, 2021 | 12.63 Mn |
| Dec 31, 2020 | 9.40 Mn |
| Jun 30, 2020 | 12.70 Mn |
| Dec 31, 2019 | 7.14 Mn |
| Sep 30, 2019 | 9.95 Mn |